Enevold Anders, Nkya Watoky M M M, Theisen Michael, Vestergaard Lasse S, Jensen Anja Tr, Staalsoe Trine, Theander Thor G, Bygbjerg Ib C, Alifrangis Michael
Centre for Medical Parasitology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Malar J. 2007 Nov 16;6:153. doi: 10.1186/1475-2875-6-153.
In malaria endemic areas children may recover from malaria after chemotherapy in spite of harbouring genotypically drug-resistant Plasmodium falciparum. This phenomenon suggests that there is a synergy between drug treatment and acquired immunity. This hypothesis was examined in an area of moderately intense transmission of P. falciparum in Tanzania during a drug trail with sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ).
One hundred children with uncomplicated malaria were treated with either SP or AQ and followed for 28 days. Mutations in parasite genes related to SP and AQ-resistance as well as human sickle cell trait and alpha-thalassaemia were determined using PCR and sequence-specific oligonucleotide probes and enzyme-linked immunosorbent assay (SSOP-ELISA), and IgG antibody responses to a panel of P. falciparum antigens were assessed and related to treatment outcome.
Parasitological or clinical treatment failure (TF) was observed in 68% and 38% of children receiving SP or AQ, respectively. In those with adequate clinical and parasitological response (ACPR) compared to children with TF, and for both treatment regimens, prevalence and levels of anti-Glutamate-rich Protein (GLURP)-specific IgG antibodies were significantly higher (P < 0.001), while prevalence of parasite haplotypes associated with SP and AQ resistance was lower (P = 0.02 and P = 0.07, respectively). Interestingly, anti-GLURP-IgG antibodies were more strongly associated with treatment outcome than parasite resistant haplotypes, while the IgG responses to none of the other 11 malaria antigens were not significantly associated with ACPR.
These findings suggest that GLURP-specific IgG antibodies in this setting contribute to clearance of drug-resistant infections and support the hypothesis that acquired immunity enhances the clinical efficacy of drug therapy. The results should be confirmed in larger scale with greater sample size and with variation in transmission intensity.
在疟疾流行地区,尽管儿童体内携带着基因型耐药的恶性疟原虫,但化疗后仍可能从疟疾中康复。这一现象表明药物治疗与获得性免疫之间存在协同作用。在坦桑尼亚一个恶性疟原虫传播强度中等的地区,在使用磺胺多辛 - 乙胺嘧啶(SP)或阿莫地喹(AQ)进行药物试验期间,对这一假设进行了检验。
100名非重症疟疾儿童接受SP或AQ治疗,并随访28天。使用聚合酶链反应(PCR)、序列特异性寡核苷酸探针和酶联免疫吸附测定(SSOP - ELISA)确定与SP和AQ耐药相关的寄生虫基因突变以及人类镰状细胞性状和α地中海贫血,并评估对一组恶性疟原虫抗原的IgG抗体反应,并将其与治疗结果相关联。
接受SP或AQ治疗的儿童中,分别有68%和38%出现寄生虫学或临床治疗失败(TF)。与TF儿童相比,在临床和寄生虫学反应充分(ACPR)的儿童中,对于两种治疗方案,抗富含谷氨酸蛋白(GLURP)特异性IgG抗体的流行率和水平均显著更高(P < 0.001),而与SP和AQ耐药相关的寄生虫单倍型流行率较低(分别为P = 0.02和P = 0.07)。有趣的是,抗GLURP - IgG抗体与治疗结果的相关性比寄生虫耐药单倍型更强,而对其他11种疟疾抗原中任何一种的IgG反应与ACPR均无显著相关性。
这些发现表明,在这种情况下,GLURP特异性IgG抗体有助于清除耐药感染,并支持获得性免疫增强药物治疗临床疗效这一假设。结果应在更大规模、更大样本量以及不同传播强度的情况下得到证实。